Clinical trial NCT03972527: Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
Official title: Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients With Head and Neck Cancer Receiving Radiation Therapy With or Without Concurrent Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oral Mucositis (Ulcerative)
Oral Mucositis (Ulcerative) Due to Radiation
Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy
Head and Neck Cancer
Keywords: photobiomodulation
LLLT (low-level laser therapy)
low-level laser therapy
oral mucositis
wound healing
radiation therapy
chemotherapy
antineoplastic therapy
side effects
phototherapy
low-level light therapy
Lead sponsor: MuReva Phototherapy Inc.
Sponsor class: INDUSTRY
First posted: 2019-06-03
Enrollment: 85
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A prospective, multi-center, randomized, double-blind, placebo controlled, adaptive sample size, two-treatment parallel, pivotal clinical study.
Primary purpose: SUPPORTIVE_CARE

Brief summary: The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the severity of oral mucositis (OM) in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, tonsils and base of tongue receiving radiation therapy with or without concurrent chemotherapy.

Detailed description: Study Design: A prospective, multi-center, randomized, double-blind, placebo controlled, adaptive sample size, two-treatment parallel, pivotal clinical study.

Protocol-eligible subjects will be randomized in a 1:1 allocation to receive either the active MuReva Phototherapy System or a sham control. Both the subjects and clinician evaluating the patients will be blinded to the treatment assignments. The sham device will be placed in the patient's mouth and operated in the same manner as the active device, but not deliver any therapy.

Subjects will begin device treatment sessions on the first day of radiation treatment (RT) and will continue to receive once daily treatments prior to RT with their assigned device for 5 days per week for the duration of their RT treatment (approximately 6 to 8 weeks, for a total of 30 to 40 device sessions depending on the standard of care regimen for the type of cancer). Each device treatment session will last approximately 10 minutes in total. Light therapy parameters for the MuReva Phototherapy System will be as follows for all subjects receiving active light therapy: 660nm, 2-12 J/cm2 nominal fluence. Subjects who stay on RT treatment past 6 weeks will continue to receive treatment with their assigned devices up through 8 total weeks of treatment (for a maximum total of 40 phototherapy sessions). In addition, all subjects, regardless of randomization, will be kept on standard oral care, oral hygiene and oral pain protocols.

All subjects will visit the study site once during the Screening period (Days -28 to 1) and an anticipated 30 to 40 times during the treatment period (i.e., 5 days during each of the 6-8 RT treatment weeks). Weekly, subjects will be evaluated for oral mucositis and for device safety. The weekly assessments will continue through the final RT session. A post-therapy assessment will be done approximately 2 weeks after completion of RT. At the conclusion of this assessment each subject's participation in the study will be complete.

Eligibility criteria: INCLUSION CRITERIA

1. Subject has been diagnosed with pathologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, tonsil or base of tongue.
2. Within 28 days of Screening, subject is scheduled to receive a continuous course of Intensity-Modulated Radiation Therapy (IMRT) over an estimated 6 to 8 weeks (treatment week is defined as 5 fractions per week). The initial target volume encompassing the gross and subclinical disease sites will receive 5 fractions per week with a minimum cumulative dose of 50 Gray (Gy) for low to intermediate risk (sites of suspected subclinical spread) and maximum cumulative dose of 70 Gy for gross tumor volume/High risk (Primary tumor and involved lymph nodes).
3. The subject's planned radiation treatment fields include a minimum of 50 Gy to at least two oral cavity sites (i.e. buccal mucosa, floor of mouth, ventral tongue, lateral tongue, dorsal tongue, hard palate, and soft palate).
4. If the subject is receiving concurrent chemotherapy, the treatment plan includes Cisplatin administered in either a standard weekly (30-40 mg/m2) or approximately every 21 days (80-100mg/m2) regimen OR Carboplatin administered in standard weekly (1.0-2.0 AUC) regimen WITH/WITHOUT Paclitaxel administered in a standard weekly (30-45mg/m2) regimen.
5. Subject is at least 22 years of age.
6. Subject has no dental or oral health conditions that would preclude daily use of a mouthpiece and demonstrates capability in sustaining mouthpiece in oral cavity for recommended time during Screening procedure.
7. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
8. Subject is able to read and understand the Informed Consent Form (ICF) and has voluntarily provided written informed consent.
9. For the entire duration of their treatment, the subject will not use any tobacco or nicotine products with the exception of nicotine patches.
10. For the entire duration of their treatment, the subject will not use any inhaled cannabis products or any illicit drugs.

EXCLUSION CRITERIA

1. Subject is currently receiving or has previously received chemotherapy or chemoradiotherapy within the past 2 years and the oral cavity has not yet fully recovered.
2. Subject is given neo-adjuvant or induction chemotherapy for Head and Neck cancer prior to starting RT.
3. Subject has been diagnosed with another type/site of cancer that has not been controlled.
4. Subject is pregnant or nursing.
5. Subject is receiving medications indicated for the treatment and/or prevention of mucositis (e.g., palifermin).
6. Subject has had prior radiation to the head and neck.
7. Subject has a diagnosis that is prone to affect wound healing, e.g., uncontrolled diabetes.
8. Subject has trismus with an interincisal distance of 30mm or less.
9. Subject has an active infection in the oropharynx and/or oral cavity (any infection in the oropharynx and/or oral cavity at the time of screening must be addressed prior to first radiation treatment).
10. Subject has a salivary disturbance, e.g., Sjögren's syndrome.
11. Subject has any grade of oral mucositis per WHO Oral Toxicity Scale.
12. Subject is receiving, or has received in the last 30 days, an investigational treatment, therapy, or medical device outside of this clinical study protocol.
13. Subject has a Baseline mouth pain score of greater than 5 out of 10 on question 6 of the OMWQ-HN. Exception can be made if Principal Investigator determines the cause of mouth pain is due to tumor or surgery site pain.
14. Subject is unable to participate in the study because of a concurrent or recent disease state that, in the opinion of the Principal Investigator, would affect the study endpoints, e.g., dental disease or COVID-19 (active or recovered).
15. Subject has 8 or more dental prostheses or implants.
16. Subject is not considered eligible at the discretion of the oral maxillofacial dentist/surgeon. Exception can be made if all items identified on the dental exam have been addressed prior to first radiation treatment.
17. Subject is receiving any medications with oral photoprotection indications.

Primary outcomes:
measure: IThe primary effectiveness endpoint is the severity of oral mucositis at week 6 of radiation treatment according to the Oral Mucositis Index (OMI) score.
timeFrame: approximately 6 weeks after patient begins radiation therapy
Secondary outcomes:
measure: World Health Organization (WHO) Oral Toxicity Scale at week 6
timeFrame: approximately 6 weeks after patient begins radiation therapy
measure: Changes in overall quality of life over the 6-week treatment period
timeFrame: difference between baseline and (approximately) 6 weeks after patient begins radiation therapy
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: Long Beach
country: United States
facility: The Oncology Institute
state: California
city: Miami
country: United States
facility: Miami Cancer Institute
state: Florida
city: Edgewood
country: United States
facility: St. Elizabeth Healthcare
state: Kentucky
city: Shreveport
country: United States
facility: Willis-Knighton Cancer Center
state: Louisiana
city: Jackson
country: United States
facility: University of Mississippi Medical Center
state: Mississippi
city: Buffalo
country: United States
facility: Erie County Medical Center
state: New York
city: New York
country: United States
facility: NYU Langone
state: New York
city: Cincinnati
country: United States
facility: The Christ Hospital
state: Ohio
city: Cleveland
country: United States
facility: MetroHealth
state: Ohio
city: Columbus
country: United States
facility: James Cancer Hospital at The Ohio State University
state: Ohio
city: Tulsa
country: United States
facility: Oklahoma Cancer Specialtists and Research Intstitute
state: Oklahoma
Study officials:
References: